Despite progress with statins, cardiovascular disease remains the leading global killer. New LDL-, triglyceride-, and Lp(a)-targeting treatments—including oral PCSK9 inhibitors and gene-editing approaches—are advancing through clinical trials and may soon redefine lipid management.
